Table 2.

Clinical outcome hazard ratio (HR) estimates for HCQ and CQ use among COVID19 patients under separate risk models.

N = 1012*		Endpoint: death						Endpoint: ICU admission						Combined endpoint
		Unadjusted			Adjusted3			Unadjusted			Adjusted4			Unadjusted			Adjusted5*
Model	Drug use	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Overall1	None (ref)	1.0			1.0			1.0			1.0			1.0			1.0
	CQ	0.64	0.47–0.88	0.007	1.01	0.71–1.44	0.937	1.50	1.05–2.13	0.024	0.91	0.63–1.31	0.619	0.94	0.74–1.18	0.590	0.97	0.75–1.24	0.795
	HCQ	0.62	0.41–0.93	0.020	0.92	0.58–1.46	0.736	0.82	0.49–1.37	0.453	0.56	0.33–0.95	0.031	0.69	0.50–0.95	0.023	0.73	0.51–1.02	0.068
Weighted Competing risk2	None (ref)	1.0												1.0			1.0
	CQ	0.86	0.61–1.21	0.392	0.99	0.70–1.43	0.991	0.93	0.64–1.35	0.708	0.80	0.55–1.15	0.207	0.85	0.67–1.10	0.205	0.85	0.66–1.10	0.224
	HCQ	0.87	0.58–1.32	0.518	0.96	0.63–1.45	0.681	0.52	0.30–0.89	0.017	0.47	0.27–0.82	0.008	0.66	0.48–0.91	0.011	0.68	0.49–0.95	0.024

¹Cox regression model without propensity score (PS) adjustment and competing regression analysis; ²competing risk regression with weighted PS adjustment (see statistical method section for explanation of the different models); HR = hazard ratio; CI = confidence interval; CQ = chloroquine; HCQ = hydroxychloroquine; *total number of patients in the analysis; ^3,4,5adjusted for gender, age, comorbidity CVA, comorbidity diabetes, comorbidity asthma/COPD, use of broad-spectrum antibiotics, therapeutic anticoagulation, prophylactic anticoagulation, first day in ED, ICU restriction.

All analyses except the competing risks regression were stratified by ICU restriction to reflect underlying potential differences in adverse incidences and risk factor prevalences.